Acadian Asset Management LLC Acquires 410,205 Shares of Alector, Inc. $ALEC

Acadian Asset Management LLC raised its holdings in shares of Alector, Inc. (NASDAQ:ALEC) by 39.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,440,661 shares of the company’s stock after purchasing an additional 410,205 shares during the period. Acadian Asset Management LLC owned 1.44% of Alector worth $1,768,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ALEC. Vestal Point Capital LP purchased a new position in shares of Alector during the 1st quarter worth approximately $621,000. Jacobs Levy Equity Management Inc. grew its holdings in shares of Alector by 25.9% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,334,032 shares of the company’s stock worth $1,641,000 after acquiring an additional 274,341 shares during the period. State of Wyoming purchased a new position in shares of Alector during the 1st quarter worth approximately $242,000. D. E. Shaw & Co. Inc. grew its holdings in shares of Alector by 93.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 368,977 shares of the company’s stock worth $697,000 after acquiring an additional 177,985 shares during the period. Finally, Walleye Capital LLC grew its holdings in shares of Alector by 108.3% during the 1st quarter. Walleye Capital LLC now owns 305,601 shares of the company’s stock worth $376,000 after acquiring an additional 158,922 shares during the period. Institutional investors own 85.83% of the company’s stock.

Alector Stock Performance

Alector stock opened at $2.76 on Wednesday. The company has a quick ratio of 3.78, a current ratio of 3.78 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $279.34 million, a P/E ratio of -2.38 and a beta of 0.99. The stock’s 50 day moving average is $2.11 and its 200 day moving average is $1.57. Alector, Inc. has a twelve month low of $0.87 and a twelve month high of $6.37.

Alector (NASDAQ:ALEC) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.15. The company had revenue of $7.87 million for the quarter, compared to the consensus estimate of $2.76 million. Alector had a negative return on equity of 112.06% and a negative net margin of 142.10%. Alector has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Alector, Inc. will post -1.88 earnings per share for the current fiscal year.

Insider Buying and Selling at Alector

In related news, Director Paula Hammond sold 14,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $2.36, for a total value of $33,040.00. Following the sale, the director owned 74,909 shares in the company, valued at $176,785.24. This represents a 15.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 20,910 shares of company stock valued at $49,255. Corporate insiders own 9.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ALEC. Wall Street Zen upgraded Alector from a “sell” rating to a “hold” rating in a report on Saturday. Mizuho upgraded Alector from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $2.50 to $3.50 in a report on Monday, July 28th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.17.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.